|
EUR million |
Used for |
2010 |
2009 |
Change % |
| Stalevo®, Comtess® / Comtan® |
Parkinson's disease |
252.7 |
234.9 |
+7.6% |
| Simdax® |
acute decompensated heart failure |
39.9 |
29.4 |
+35.5% |
| Easyhaler® product family |
asthma, COPD |
28.1 |
24.9 |
+12.8% |
| Precedex® |
intensive care sedative |
27.2 |
14.6 |
+86.7% |
| Domitor®, Dexdomitor®, Domosedan® and Antisedan® |
animal sedatives |
24.2 |
19.3 |
+25.0% |
| Burana® |
inflammatory pain |
21.5 |
19.9 |
+8.2% |
| Divina® product range |
menopausal symptoms |
13.3 |
13.2 |
+1.0% |
| Marevan® |
anticoagulant |
13.1 |
11.2 |
+16.7% |
| Enanton® |
prostate cancer |
13.0 |
11.9 |
+9.1% |
| Fareston® |
breast cancer |
11.7 |
10.2 |
+14.6% |
| Total |
|
444.6 |
389.5 |
+14.1% |
Share of pharmaceutical net
sales, % |
|
55% |
53% |
|